Active, Not Recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397
- Conditions
- Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
- Locations
-
- GSK Investigational Site Birmingham, Alabama, United States
- GSK Investigational Site Los Angeles, California, United States
- GSK Investigational Site Los Angeles, California, United States
- GSK Investigational Site Los Angeles, California, United States